{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:07Z","timestamp":1794047527771,"version":"4.8.0"},"reference-count":79,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>von Willebrand disease (VWD) is a hereditary bleeding disorder first described by Erik von Willebrand in 1926. The disease is characterized by frequent bruising, bleeding from minor wounds, nosebleeds, heavy menstrual bleeding, bleeding after tooth extraction, gastrointestinal bleeding, and joint bleeds. The underlying cause of VWD was identified 45 years later as a deficiency of von Willebrand factor (VWF), a high-molecular-weight protein that circulates with factor VIII in plasma. The clinical diagnosis of VWD involves the presence of bleeding symptoms, detection of at least one abnormality of VWF function in laboratory tests, and demonstration of familial inheritance. VWD presents a broad spectrum of clinical and laboratory abnormalities, making the diagnostic process complex. Integrating clinical and laboratory data into the diagnostic pathway using a Bayesian approach can help build evidence for a diagnosis. Over the years, several diagnostic assays have been developed to measure the quantitative and qualitative properties of VWF. Automated laboratory assays for measuring VWF have been implemented in recent decades, and assessment tools for clinical evaluation of bleeding severity have been developed. Laboratory diagnosis involves screening and first-level diagnostic tests to measure VWF antigen, VWF-platelet binding activity, and factor VIII coagulant activity. Second-level subtyping tests are required to characterize the phenotypic defects of the type 2 variants and classify the patients. Proper diagnosis and classification of VWD are essential in order to recognize patients who may benefit from treatment, determine the optimal treatment modality, and prevent overdiagnosis.<\/jats:p>","DOI":"10.3324\/haematol.2024.286011","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T19:57:07Z","timestamp":1767297427000},"page":"35-43","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and laboratory diagnosis of von Willebrand disease"],"prefix":"10.3324","volume":"111","author":[{"given":"Alberto","family":"Tosetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Eikenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"83218","doi-asserted-by":"crossref","unstructured":"Von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia. 1999; 5(3):223-231.","DOI":"10.1046\/j.1365-2516.1999.00302.x"},{"key":"83219","unstructured":"von Willebrand EA. Hereditar pseudohemofili. Fin Lakaresallsk Handl. 1926; 672:7-112."},{"key":"83220","doi-asserted-by":"crossref","unstructured":"Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand\u2019s disease: with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971; 50(1):244-254.","DOI":"10.1172\/JCI106480"},{"key":"83221","doi-asserted-by":"crossref","unstructured":"Fogarty H, Doherty D, O\u2019Donnell JS. New developments in von Willebrand disease. Br J Haematol. 2020; 191(3):329-339.","DOI":"10.1111\/bjh.16681"},{"key":"83222","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev. 2007; 21(2):89-97.","DOI":"10.1016\/j.blre.2006.04.002"},{"key":"83223","doi-asserted-by":"crossref","unstructured":"Kalot MA, Husainat N, Tayiem S. Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Adv. 2021; 5(23):5023-5031.","DOI":"10.1182\/bloodadvances.2021004368"},{"key":"83224","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Tosetto A. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology Am Soc Hematol Educ Program. 2009;113-123.","DOI":"10.1182\/asheducation-2009.1.113"},{"key":"83225","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009; 114(6):1158-1165.","DOI":"10.1182\/blood-2009-01-153296"},{"key":"83226","doi-asserted-by":"crossref","unstructured":"Poston JN, Kruse-Jarres R. How I treat von Willebrand disorders in older adults. Blood. 2024; 143(3):197-204.","DOI":"10.1182\/blood.2022018534"},{"key":"83227","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. Blood. 2015; 125(6):907-914.","DOI":"10.1182\/blood-2014-08-551960"},{"key":"83228","doi-asserted-by":"crossref","unstructured":"Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1: on behalf of the ISTH SSC Subcommittee on von Willebrand Factor. J Thromb Haemost. 2005; 3(4):775-777.","DOI":"10.1111\/j.1538-7836.2005.01245.x"},{"key":"83229","doi-asserted-by":"crossref","unstructured":"James PD, Connell NT, Ameer B. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021; 5(1):280-300.","DOI":"10.1182\/bloodadvances.2020003265"},{"key":"83230","doi-asserted-by":"crossref","unstructured":"Tosetto A, Rodeghiero F, Castaman G. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006; 4(4):766-773.","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"83231","doi-asserted-by":"crossref","unstructured":"Tosetto A, Badiee Z, Baghaipour MR. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study. J Thromb Haemost. 2020; 18(9):2145-2154.","DOI":"10.1111\/jth.14886"},{"key":"83232","doi-asserted-by":"crossref","unstructured":"Lavin M, Aguila S, Schneppenheim S. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017; 130(21):2344-2353.","DOI":"10.1182\/blood-2017-05-786699"},{"key":"83233","doi-asserted-by":"crossref","unstructured":"Seidizadeh O, Ciavarella A, Baronciani L. Clinical and laboratory presentation and underlying mechanism in patients with low VWF. Thromb Haemost. 2024; 124(4):340-350.","DOI":"10.1055\/a-2186-6362"},{"key":"83234","doi-asserted-by":"crossref","unstructured":"Atiq F, Blok R, van Kwawegen CB. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies. Blood. 2024; 143(14):1414-1424.","DOI":"10.1182\/blood.2023022457"},{"key":"83235","doi-asserted-by":"crossref","unstructured":"Bours MJL. Bayes\u2019 rule in diagnosis. J Clin Epidemiol. 2021; 131:158-160.","DOI":"10.1016\/j.jclinepi.2020.12.021"},{"key":"83236","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand\u2019s disease. Blood. 1987; 69(2):454-459.","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"83237","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost. 2011; 9(6):1143-1148.","DOI":"10.1111\/j.1538-7836.2011.04265.x"},{"key":"83238","doi-asserted-by":"crossref","unstructured":"Sanders YV, Giezenaar MA, Laros-van Gorkom BA. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost. 2014; 12(7):1066-1075.","DOI":"10.1111\/jth.12586"},{"key":"83239","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Rodeghiero F. Bleeders, bleeding rates, and bleeding score. J Thromb Haemost. 2013; 11(Suppl 1):142-150.","DOI":"10.1111\/jth.12248"},{"key":"83240","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Tosetto A, Abshire T. ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010; 8(9):2063-2065.","DOI":"10.1111\/j.1538-7836.2010.03975.x"},{"key":"83241","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Tosetto A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005; 3(12):2619-2626.","DOI":"10.1111\/j.1538-7836.2005.01663.x"},{"key":"83242","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools?. Haemophilia. 2008; 14(3):415-422.","DOI":"10.1111\/j.1365-2516.2007.01648.x"},{"key":"83243","doi-asserted-by":"crossref","unstructured":"Federici AB, Bucciarelli P, Castaman G. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014; 123(26):4037-4044.","DOI":"10.1182\/blood-2014-02-557264"},{"key":"83244","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood. 2008; 111(8):3998-4003.","DOI":"10.1182\/blood-2007-08-105940"},{"key":"83245","doi-asserted-by":"crossref","unstructured":"Elbatarny M, Mollah S, Grabell J. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014; 20(6):831-835.","DOI":"10.1111\/hae.12503"},{"key":"83246","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Pabinger I, Ragni M. Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA consensus report. Hemasphere. 2019; 3(5):e286.","DOI":"10.1097\/HS9.0000000000000286"},{"key":"83247","doi-asserted-by":"crossref","unstructured":"Stokhuijzen E, Rand ML, Cnossen MH. Identifying Children with HEreditary Coagulation disorders (iCHEC): a protocol for a prospective cohort study. BMJ Open. 2018; 8(5):e020686.","DOI":"10.1136\/bmjopen-2017-020686"},{"key":"83248","doi-asserted-by":"crossref","unstructured":"Favaloro EJ, Bonar R. External quality assessment\/proficiency testing and internal quality control for the PFA-100 and PFA-200: an update. Semin Thromb Hemost. 2014; 40(2):239-253.","DOI":"10.1055\/s-0034-1365844"},{"key":"83249","doi-asserted-by":"crossref","unstructured":"Weyand AC, Flood VH. Von Willebrand disease: current status of diagnosis and management. Hematol Oncol Clin North Am. 2021; 35(6):1085-1101.","DOI":"10.1016\/j.hoc.2021.07.004"},{"key":"83250","doi-asserted-by":"crossref","unstructured":"Federici AB, Mannucci PM, Castaman G. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009; 113(3):526-534.","DOI":"10.1182\/blood-2008-04-152280"},{"key":"83251","doi-asserted-by":"crossref","unstructured":"Favaloro EJ. Clinical utility of closure times using the platelet function analyzer-100\/200. Am J Hematol. 2017; 92(4):398-404.","DOI":"10.1002\/ajh.24620"},{"key":"83252","doi-asserted-by":"crossref","unstructured":"Castaman G, Tosetto A, Cappelletti A. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res. 2010; 126(3):227-231.","DOI":"10.1016\/j.thromres.2010.06.013"},{"key":"83253","doi-asserted-by":"crossref","unstructured":"Ziemba YC, Abdulrehman J, Hollestelle MJ. Diagnostic testing for von Willebrand disease: trends and insights from North American laboratories over the last decade. Semin Thromb Hemost. 2022; 48(6):700-710.","DOI":"10.1055\/s-0042-1754332"},{"key":"83254","doi-asserted-by":"crossref","unstructured":"Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand\u2019s disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest. 1973; 52(11):2708-2716.","DOI":"10.1172\/JCI107465"},{"key":"83255","doi-asserted-by":"crossref","unstructured":"Bodo I, Eikenboom J, Montgomery R. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015; 13(7):1345-1350.","DOI":"10.1111\/jth.12964"},{"key":"83256","doi-asserted-by":"crossref","unstructured":"Flood VH, Gill JC, Morateck PA. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010; 116(2):280-286.","DOI":"10.1182\/blood-2009-10-249102"},{"key":"83257","doi-asserted-by":"crossref","unstructured":"Christopherson PA, Haberichter SL, Flood VH, Sicking UO, Abshire TC, Montgomery RR. Ristocetin dependent cofactor activity in von Willebrand disease diagnosis: limitations of relying on a single measure. Res Pract Thromb Haemost. 2022; 6(7):e12807.","DOI":"10.1002\/rth2.12807"},{"key":"83258","doi-asserted-by":"crossref","unstructured":"Kalot MA, Husainat N, Abughanimeh O. Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. Blood Adv. 2022; 6(12):3735-3745.","DOI":"10.1182\/bloodadvances.2021005431"},{"key":"83259","doi-asserted-by":"crossref","unstructured":"Knol HM, Kemperman RF, Kluin-Nelemans HC, Mulder AB, Meijer K. Haemostatic variables during normal menstrual cycle. A systematic review. Thromb Haemost. 2012; 107(1):22-29.","DOI":"10.1160\/TH11-07-0481"},{"key":"83260","doi-asserted-by":"crossref","unstructured":"Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003; 101(6):2089-2093.","DOI":"10.1182\/blood-2002-09-2892"},{"key":"83261","doi-asserted-by":"crossref","unstructured":"Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program. 2009;106-112.","DOI":"10.1182\/asheducation-2009.1.106"},{"key":"83262","doi-asserted-by":"crossref","unstructured":"Bucciarelli P, Siboni SM, Stufano F. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. J Thromb Haemost. 2015; 13(2):228-236.","DOI":"10.1111\/jth.12799"},{"key":"83263","doi-asserted-by":"crossref","unstructured":"Leebeek FW, Eikenboom JC. Von Willebrand\u2019s disease. N Engl J Med. 2016; 375(21):2067-2080.","DOI":"10.1056\/NEJMra1601561"},{"key":"83264","doi-asserted-by":"crossref","unstructured":"Kalot MA, Husainat N, El Alayli A. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Adv. 2022; 6(1):62-71.","DOI":"10.1182\/bloodadvances.2021005430"},{"key":"83265","doi-asserted-by":"crossref","unstructured":"Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost. 2006; 32(5):514-521.","DOI":"10.1055\/s-2006-947866"},{"key":"83266","doi-asserted-by":"crossref","unstructured":"Bowyer AE, Goodfellow KJ, Seidel H. Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European centers. Res Pract Thromb Haemost. 2018; 2(4):790-799.","DOI":"10.1002\/rth2.12141"},{"key":"83267","doi-asserted-by":"crossref","unstructured":"Seidizadeh O, Eikenboom JCJ, Denis CV. von Willebrand disease. Nat Rev Dis Primers. 2024; 10(1):51.","DOI":"10.1038\/s41572-024-00536-8"},{"key":"83268","doi-asserted-by":"crossref","unstructured":"Frontroth JP, Favaloro EJ. Ristocetin-induced platelet aggregation (RIPA) and RIPA mixing studies. Methods Mol Biol. 2017; 1646:473-494.","DOI":"10.1007\/978-1-4939-7196-1_35"},{"key":"83269","doi-asserted-by":"crossref","unstructured":"Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost. 2011; 37(5):464-469.","DOI":"10.1055\/s-0031-1281030"},{"key":"83270","doi-asserted-by":"crossref","unstructured":"Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol. 2002; 117(3):716-718.","DOI":"10.1046\/j.1365-2141.2002.03488.x"},{"key":"83271","doi-asserted-by":"crossref","unstructured":"Mohammed S, Favaloro EJ. Laboratory testing for von Willebrand factor: factor VIII binding (for 2N VWD). Methods Mol Biol. 2017; 1646:461-472.","DOI":"10.1007\/978-1-4939-7196-1_34"},{"key":"83272","doi-asserted-by":"crossref","unstructured":"Borchiellini A, Fijnvandraat K, ten Cate JW. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996; 88(8):2951-2958.","DOI":"10.1182\/blood.V88.8.2951.bloodjournal8882951"},{"key":"83273","doi-asserted-by":"crossref","unstructured":"Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67:395-424.","DOI":"10.1146\/annurev.biochem.67.1.395"},{"key":"83274","doi-asserted-by":"crossref","unstructured":"Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A. 1987; 84(7):1955-1959.","DOI":"10.1073\/pnas.84.7.1955"},{"key":"83275","doi-asserted-by":"crossref","unstructured":"Eikenboom J, Federici AB, Dirven RJ. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013; 121(12):2336-2339.","DOI":"10.1182\/blood-2012-09-455089"},{"key":"83276","doi-asserted-by":"crossref","unstructured":"Seidizadeh O, Baronciani L, Pagliari MT. Genetic determinants of enhanced von Willebrand factor clearance from plasma. J Thromb Haemost. 2023; 21(5):1112-1122.","DOI":"10.1016\/j.jtha.2023.01.012"},{"key":"83277","doi-asserted-by":"crossref","unstructured":"Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994; 71(4):520-525.","DOI":"10.1055\/s-0038-1642471"},{"key":"83278","doi-asserted-by":"crossref","unstructured":"Seidizadeh O, Mollica L, Zambarbieri S. Type 2M\/2A von Willebrand disease: a shared phenotype between type 2M and 2A. Blood Adv. 2024; 8(7):1725-1736.","DOI":"10.1182\/bloodadvances.2024012626"},{"key":"83279","doi-asserted-by":"crossref","unstructured":"Borr\u00e0s N, Batlle J, P\u00e9rez-Rodr\u00edguez A. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica. 2017; 102(12):2005-2014.","DOI":"10.3324\/haematol.2017.168765"},{"key":"83280","doi-asserted-by":"crossref","unstructured":"Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004; 111(7):734-740.","DOI":"10.1111\/j.1471-0528.2004.00176.x"},{"key":"83281","doi-asserted-by":"crossref","unstructured":"Westbury SK, Turro E, Greene D. Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Med. 2015; 7(1):36.","DOI":"10.1186\/s13073-015-0151-5"},{"key":"83282","doi-asserted-by":"crossref","unstructured":"Mauer AC, Barbour EM, Khazanov NA, Levenkova N, Mollah SA, Coller BS. Creating an ontology-based human phenotyping system: the Rockefeller University bleeding history experience. Clin Transl Sci. 2009; 2(5):382-385.","DOI":"10.1111\/j.1752-8062.2009.00147.x"},{"key":"83283","unstructured":"Gargano MA, Matentzoglu N, Coleman B. The human phenotype ontology in 2024: phenotypes around the world. Nucleic Acids Res. 2023; 52(D1):D1333-D1346."},{"key":"83284","doi-asserted-by":"crossref","unstructured":"Connell NT, Flood VH, Brignardello-Petersen R. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021; 5(1):301-325.","DOI":"10.1182\/bloodadvances.2020003264"},{"key":"83285","doi-asserted-by":"crossref","unstructured":"Atiq F, Heijdra JM, Snijders F. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Adv. 2022; 6(18):5317-5326.","DOI":"10.1182\/bloodadvances.2021006757"},{"key":"83286","doi-asserted-by":"crossref","unstructured":"Seidizadeh O, Peyvandi F, Mannucci PM. Von Willebrand disease type 2N: an update. J Thromb Haemost. 2021; 19(4):909-916.","DOI":"10.1111\/jth.15247"},{"key":"83287","doi-asserted-by":"crossref","unstructured":"Castaman G, Federici AB, Tosetto A. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012; 10(4):632-638.","DOI":"10.1111\/j.1538-7836.2012.04661.x"},{"key":"83288","doi-asserted-by":"crossref","unstructured":"Higham JM, O\u2019Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990; 97(8):734-739.","DOI":"10.1111\/j.1471-0528.1990.tb16249.x"},{"key":"83289","doi-asserted-by":"crossref","unstructured":"AlSaleh KA, Al-Numair NS, Alsuaiman A. Prevalence of bleeding symptoms among young adults in Saudi Arabia, a national survey. Trial User. 2021; 100(43)","DOI":"10.1097\/MD.0000000000027513"},{"key":"83290","doi-asserted-by":"crossref","unstructured":"Castaman G, Katsarou O, Jansen N, Santos S, Escolar G, Berntorp E. Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews. Haemophilia. 2023; 29(2):411-422.","DOI":"10.1111\/hae.14655"},{"key":"83291","doi-asserted-by":"crossref","unstructured":"Mauer AC, Khazanov NA, Levenkova N. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost. 2011; 9(1):100-108.","DOI":"10.1111\/j.1538-7836.2010.04105.x"},{"key":"83292","unstructured":"Silwer J. von Willebrand\u2019s disease in Sweden. Acta Paediatr Scand Suppl. 1973; 238:1-159."},{"key":"83293","doi-asserted-by":"crossref","unstructured":"Federici AB, Castaman G, Mannucci PM, Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia. 2002; 8(5):607-621.","DOI":"10.1046\/j.1365-2516.2002.00672.x"},{"key":"83294","doi-asserted-by":"crossref","unstructured":"Wahlberg T, Blomback M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf Med. 1980; 19(4):194-200.","DOI":"10.1055\/s-0038-1635279"},{"key":"83295","doi-asserted-by":"crossref","unstructured":"Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost. 1988; 59(3):349-352.","DOI":"10.1055\/s-0038-1647493"},{"key":"83296","doi-asserted-by":"crossref","unstructured":"Quiroga T, Goycoolea M, Panes O. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica. 2007; 92(3):357-365.","DOI":"10.3324\/haematol.10816"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286011\/79197","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286011\/79259","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/13055\/79197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:44Z","timestamp":1794046244000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286011","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}